Donald L. Sweet

1.6k total citations
33 papers, 1.2k citations indexed

About

Donald L. Sweet is a scholar working on Pathology and Forensic Medicine, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Donald L. Sweet has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 13 papers in Genetics and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Donald L. Sweet's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Viral-associated cancers and disorders (4 papers). Donald L. Sweet is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Viral-associated cancers and disorders (4 papers). Donald L. Sweet collaborates with scholars based in United States, United Kingdom and Japan. Donald L. Sweet's co-authors include Daina Variakojis, Harvey M. Golomb, Richard S. Stein, Arthur R. Gaba, John E. Ultmann, Jacob D. Bitran, John B. Miller, Janet D. Rowley, Jeannie J. Kinzie and William W. Weddington and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Donald L. Sweet

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald L. Sweet United States 18 625 568 290 223 178 33 1.2k
Shimareet Kumar United States 19 758 1.2× 567 1.0× 173 0.6× 155 0.7× 65 0.4× 26 1.3k
W.Y. Au China 18 534 0.9× 448 0.8× 230 0.8× 147 0.7× 132 0.7× 57 1.1k
Hirofumi Taji Japan 19 654 1.0× 603 1.1× 169 0.6× 200 0.9× 83 0.5× 35 1.2k
Maurizio Musso Italy 19 334 0.5× 364 0.6× 243 0.8× 110 0.5× 75 0.4× 68 1.4k
John Amess United Kingdom 12 619 1.0× 445 0.8× 358 1.2× 124 0.6× 107 0.6× 16 1.3k
Stephen H. Nantel Canada 20 339 0.5× 303 0.5× 386 1.3× 177 0.8× 59 0.3× 74 1.3k
B. W. Hancock United Kingdom 16 434 0.7× 487 0.9× 203 0.7× 111 0.5× 28 0.2× 52 1.3k
Xavier Rialland France 23 317 0.5× 235 0.4× 510 1.8× 391 1.8× 44 0.2× 45 1.6k
Razelle Kurzrock United States 18 329 0.5× 178 0.3× 288 1.0× 49 0.2× 70 0.4× 24 1.1k
Ayad Atra United Kingdom 16 194 0.3× 190 0.3× 89 0.3× 129 0.6× 44 0.2× 48 820

Countries citing papers authored by Donald L. Sweet

Since Specialization
Citations

This map shows the geographic impact of Donald L. Sweet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald L. Sweet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald L. Sweet more than expected).

Fields of papers citing papers by Donald L. Sweet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald L. Sweet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald L. Sweet. The network helps show where Donald L. Sweet may publish in the future.

Co-authorship network of co-authors of Donald L. Sweet

This figure shows the co-authorship network connecting the top 25 collaborators of Donald L. Sweet. A scholar is included among the top collaborators of Donald L. Sweet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald L. Sweet. Donald L. Sweet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mehta, Amit, et al.. (2021). Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk. Acta Haematologica. 145(2). 221–228. 7 indexed citations
2.
Sweet, Donald L. & John E. Ultmann. (2015). Chemotherapy of Non-Hodgkin Lymphoma: the Diffuse Types. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 24. 125–133.
3.
Moss, Thomas J., Douglas Kahn, Nancy E. Warner, et al.. (1995). Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.. PubMed. 15(6). 929–33. 20 indexed citations
4.
Massa, Mary C., et al.. (1984). Angiolymphoid hyperplasia demonstrating extensive skin and mucosal lesions controlled with vinblastine therapy. Journal of the American Academy of Dermatology. 11(2). 333–339. 30 indexed citations
5.
Larson, Richard A., Donald L. Sweet, Harvey M. Golomb, Joseph R. Testa, & Janet D. Rowley. (1982). Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer. 49(11). 2222–2225. 8 indexed citations
6.
Wong, Kenneth K., Donald L. Sweet, & Daina Variakojis. (1982). The treatment of lymphoblastic lymphoma with antithymocyte globulin. Cancer. 50(1). 57–61. 4 indexed citations
7.
Kanofsky, Jeffrey R., et al.. (1982). Treatment of lymphoid malignancies with 2'-deoxycoformycin A pilot study. American Journal of Clinical Oncology. 5(2). 179–184. 13 indexed citations
8.
Sweet, Donald L.. (1982). Hospice: Prescription for Terminal Care (review). Perspectives in biology and medicine. 25(2). 333–334. 1 indexed citations
9.
Kanofsky, Jeffrey R., et al.. (1981). Late relapses in hodgkin disease. American Journal of Hematology. 10(1). 31–36. 12 indexed citations
10.
Miller, John B., Daina Variakojis, Jacob D. Bitran, et al.. (1981). Diffuse histiocytic lymphoma with sclerosis: A clinicopathologic entity frequently causing superior venacaval obstruction. Cancer. 47(4). 748–756. 79 indexed citations
11.
12.
Mintz, Uri, John B. Miller, Harvey M. Golomb, et al.. (1979). Pathologic stage I and II Hodgkin's disease, 1968-1975. Relapses and results of retreatment. Cancer. 44(1). 72–79. 14 indexed citations
13.
Sweet, Donald L., et al.. (1979). Acute myelogenous leukemia and thrombocythemia associated with an abnormality of chromosome No. 3. Cancer Genetics and Cytogenetics. 1(1). 33–37. 60 indexed citations
14.
Gaba, Arthur R., Richard S. Stein, Donald L. Sweet, & Daina Variakojis. (1978). Multicentric Giant Lymph Node Hyperplasia. American Journal of Clinical Pathology. 69(1). 86–90. 264 indexed citations
15.
Mintz, Uri, Donald L. Sweet, Jacob D. Bitran, & John E. Ultmann. (1978). Lactic acidosis and diffuse histiocytic lymphoma (DHL). American Journal of Hematology. 4(4). 359–365. 14 indexed citations
16.
Bitran, Jacob D., Harvey M. Golomb, John E. Ultmann, et al.. (1978). Non-hodgkin's lymphoma, poorly differentiated lymphocytic and mixed cell types.Results of sequential staging procedures, response to therapy, and survival of 100 patients. Cancer. 42(1). 88–95. 37 indexed citations
17.
Golomb, Harvey M., et al.. (1978). Hairy Cell Leukaemia: Evidence for the Existence of a Spectrum of Functional Characteristics. British Journal of Haematology. 38(2). 161–170. 49 indexed citations
18.
Sweet, Donald L., Harvey M. Golomb, & John E. Ultmann. (1977). Chronic Lymphocytic Leukaemia and its Relationship to Other Lymphoproliferative Disorders. Clinics in Haematology. 6(1). 141–157. 17 indexed citations
19.
Sweet, Donald L., et al.. (1976). Avascular Necrosis of the Femoral Head with Combination Therapy. Annals of Internal Medicine. 85(1). 67–68. 33 indexed citations
20.
Sweet, Donald L., et al.. (1975). CHEMOTHERAPY OF ADVANCED HISTIOCYTIC LYMPHOMAS. The Lancet. 305(7916). 1136–1136.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shimareet Kumar Breakdown of academic impact, for papers by W.Y. Au Breakdown of academic impact, for papers by Hirofumi Taji Breakdown of academic impact, for papers by Maurizio Musso Breakdown of academic impact, for papers by John Amess Breakdown of academic impact, for papers by Stephen H. Nantel Breakdown of academic impact, for papers by B. W. Hancock Breakdown of academic impact, for papers by Xavier Rialland Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Ayad Atra
Rankless by CCL
2026